Renee R. Anderko

Renee R. Anderko

Auto-generated profile, based on publicly available information

Renee R. Anderko

Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
RARenee R Anderko
Renee R Anderko
Robbie B. MailliardRobbie B. Mailliard
Robbie B. Mailliard
Although highly effective at durably suppressing plasma HIV-1 viremia, combination antiretroviral therapy (ART) treatment regimens do not eradicate the virus, which persists in long-lived CD4+ T cells. This latent viral reservoir serves as a source of plasma viral rebound following treatment interruption, thus requiring lifelong adherence to ART. Additionally, challenges remain related not only to access to therapy but also to a higher prevalence of comorbidities with an inflammatory etiology in treated HIV-1+ individuals, underscoring the need to explore therapeutic alternatives that achieve sustained virologic remission in the absence of ART. Natural killer (NK) cells are uniquely positioned to positively impact antiviral immunity, in part due to the pleiotropic nature of their effector functions, including the acquisition of memory-like features, and, therefore, hold great promise for transforming HIV-1 therapeutic modalities. In addition to defining the ability of NK cells to contribute to HIV-1 control, this review provides a basic immunologic understanding of the impact of HIV-1 infection and ART on the phenotypic and functional character of NK cells. We further delineate the qualities of “memory” NK cell populations, as well as the impact of HCMV on their induction and subsequent expansion in HIV-1 infection. We conclude by highlighting promising avenues for optimizing NK cell responses to improve HIV-1 control and effect a functional cure, including blockade of inhibitory NK receptors, TLR agonists to promote latency reversal and NK cell activation, CAR NK cells, BiKEs/TriKEs, and the role of HIV-1-specific bNAbs in NK cell–mediated ADCC activity against HIV-1-infected cells.

29 March 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
RARenee R. Anderko
Renee R. Anderko
ADAllison E DePuyt
Allison E DePuyt
RBRhianna Bronson
Rhianna Bronson
ABArlene C. Bullotta
Arlene C. Bullotta
EAEvgenia Aga
Evgenia Aga
Robbie B. MailliardRobbie B. Mailliard
Robbie B. Mailliard
HIV-1 infection greatly alters the NK cell phenotypic and functional repertoire. This is highlighted by the expansion of a rare population of FcRγ– NK cells exhibiting characteristics of traditional immunologic memory in people with HIV (PWH). Although current antiretroviral therapy (ART) effectively controls HIV-1 viremia and disease progression, its impact on HIV-1–associated NK cell abnormalities remains unclear. To address this, we performed a longitudinal analysis detailing conventional and memory-like NK cell characteristics in n = 60 PWH during the first 4 y of ART. Throughout this regimen, a skewed repertoire of cytokine unresponsive FcRγ– memory-like NK cells persisted and accompanied an overall increase in NK surface expression of CD57 and KLRG1, suggestive of progression toward immune senescence. These traits were linked to elevated serum inflammatory biomarkers and increasing Ab titers to human CMV, with human CMV viremia detected in approximately one-third of PWH at years 1–4 of ART. Interestingly, 40% of PWH displayed atypical NK cell subsets, representing intermediate stages of NK-poiesis based on single-cell multiomic trajectory analysis. Our findings indicate that NK cell irregularities persist in PWH despite long-term ART, underscoring the need to better understand the causative mechanisms that prevent full restoration of immune health in PWH.

13 November 2020 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
RARenee R. Anderko
Renee R. Anderko
CRCharles R. Rinaldo
Charles R. Rinaldo
Robbie B. MailliardRobbie B. Mailliard
Robbie B. Mailliard
Despite being prolific innate killers, NK cells are also key helper cells in antiviral defense, influencing adaptive immune responses via interactions with dendritic cells (DCs). In addition to causing NK cell dysfunction, HIV-1 infection contributes to the expansion of a rare population of NK cells deficient in FcRγ (FcRγ−), an intracellular adaptor protein that associates with CD16. The implications of this inflated NK cell subset in treated HIV-1 infection remain unclear. In this study, we explored the helper function of human NK cells in chronic HIV-1 infection, with a particular focus on characterizing FcRγ− NK cells. Exposure of NK cells to innate DC-derived costimulatory factors triggered their helper activity, defined by their ability to produce IFN-γ and to drive the maturation of high IL-12–producing DCs. In this setting, however, FcRγ− NK cells were defective at producing the dominant DC-polarizing agent IFN-γ. The reduced responsiveness of FcRγ− NK cells to IL-18 in particular, which was attributable to impaired inducible expression of IL-18Rα, extended beyond an inability to produce IFN-γ, as FcRγ− NK cells showed limited potential to differentiate into CD16−/CD25+/CD83+ helper cells. Notwithstanding their deficiencies in responsiveness to innate environmental cues, FcRγ− NK cells responded robustly to adaptive Ab-mediated signaling through CD16. The presence of an expanded population of FcRγ− NK cells with a diminished capacity to respond to IL-18 and to effectively modulate DC function may contribute to disturbances in proper immune homeostasis associated with HIV-1 infection and to defects in the initiation of optimal adaptive antiviral responses.

4 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
RARenee R. Anderko
Renee R. Anderko
ABAlexandra E. Bowman
Alexandra E. Bowman
PMPraneel Murthy
Praneel Murthy
ACAsmita Chopra
Asmita Chopra
NTNikhil V. Tirukkovalur
Nikhil V. Tirukkovalur
AZAmer H. Zureikat
Amer H. Zureikat
Purpose: Unsatisfactory outcomes in pancreatic ductal adenocarcinoma (PDAC) highlight the need to identify precision-based treatment modalities. We aimed to utilize patient-derived organoids (PDO) to predict the most effective individual components of potential combination therapies. Experimental Design: Autologous αβ- and γδ-enriched tumor-infiltrating lymphocyte (TIL) and PDO cultures were established from resected PDAC tissue. PDOs were characterized by immunostaining, targeted next-generation sequencing, and drug screening with standard-of-care multidrug chemotherapeutic regimens. Expanded TIL cultures were profiled through flow cytometry, sequencing, and potency against autologous PDOs. Results: PDO cultures were established with an 80% success rate. In addition to faithfully recapitulating molecular and histologic features of the parental tumor, PDOs were sufficiently expanded for pharmacotyping within a clinically relevant time frame of 36 days. Notably, PDO chemotherapeutic sensitivity profiles correlated with patient serum CA 19-9 dynamics and recurrence-free survival. Furthermore, expanded γδ-enriched TILs supported the activation of αβ TCR+ cells and demonstrated more potent functionality in response to autologous PDO targets. Importantly, infiltration of γδ T cells within pancreatic tumor tissue was associated with improved overall survival. Conclusions: We confirm the feasibility of generating PDOs within a clinically relevant time frame and provide evidence of their utility for advancing therapeutic success in PDAC.

29 October 2024 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
RARenee R Anderko
Renee R Anderko
AZAmer H Zureikat
Amer H Zureikat
TBTullia C Bruno
Tullia C Bruno
Reprogramming the PDAC tumor microenvironment via nanoparticles may help to induce tertiary lymphoid structures that support antitumor immunity.

4 February 2026
Verified
Other
Open access
RARenee R. Anderko
Renee R. Anderko
ABAlexandra E. Bowman
Alexandra E. Bowman
PMPraneel Murthy
Praneel Murthy
ACAsmita Chopra
Asmita Chopra
NTNikhil V. Tirukkovalur
Nikhil V. Tirukkovalur
AZAmer H. Zureikat
Amer H. Zureikat
γδ-enriched TIL directly and indirectly contribute to functional antitumor immune responses